Industry: Pharmaceuticals, Biotechnology
DiObex, Inc. is a San Francisco based, venture-financed biotechnology company. The company was founded in 2003 to develop novel products for the treatment of metabolic diseases. The company’s novel formulations of Very Low Dose Glucagon (VLD Glucagon) are currently undergoing clinical testing at the Mayo Clinic, University of California San Diego, Tulane University, and the Diabetes & Glandular Disease Clinic in San Antonio. The company’s second product, a novel Cortisol Synthesis Inhibitor, will enter human clinical trials in early 2006. DiObex investors are Domain Associates, Pequot Ventures and Sofinnova Ventures. ( www.diobex.com )
DiObex , Inc.
600 Townsend Street Suite 271
San Francisco, California 94103
USA
Tel: (415) 551-0400
Fax: (415) 551-4113